Tarsus Pharmaceuticals, Inc. (TARS)

Name: Tarsus Pharmaceuticals, Inc. (TARS) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001819790 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Tarsus Pharmaceuticals, Inc. reported revenue of $451.36M. Revenue grew 146.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $606.33M.

Key ratios (year ended 2025-12-31)

-15.7%

Operating margin

-14.7%

Net margin

-19.3%

Return on year-end equity

146.7%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K/A (current report) · 2026-10-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Revenue	$606.33M	$451.36M	$182.95M	$17.45M	$25.82M	$57.03M	$0	n/a	n/a
R&D Expense	$87.68M	$64.32M	$53.39M	$50.31M	$42.62M	$41.71M	$18.83M	$3.16M	n/a
Operating Income	-$48.53M	-$70.97M	-$120.57M	-$143.16M	-$62.71M	-$12.16M	-$27.00M	-$4.30M	n/a
Net Income	-$46.48M	-$66.42M	-$115.55M	-$135.89M	-$62.09M	-$13.83M	-$26.81M	-$4.67M	-$1.32M
EPS (Diluted)	n/a	-$1.59	-$3.07	-$4.62	-$2.52	-$0.67	-$4.32	n/a	n/a
Total Assets	$611.14M	$562.16M	$376.99M	$265.49M	$227.86M	$178.91M	$171.97M	$58.32M	n/a
Total Liabilities	$264.41M	$218.73M	$152.46M	$68.50M	$34.96M	$12.18M	$5.99M	$919.0K	n/a
Long-Term Debt	$72.76M	$72.44M	$71.84M	$29.82M	$19.43M	n/a	n/a	n/a	n/a
Shareholders' Equity	$346.73M	$343.43M	$224.53M	$196.99M	$192.90M	$166.73M	$165.98M	-$6.00M	-$1.35M
Cash & Equivalents	$204.59M	$183.64M	$94.82M	$224.95M	$71.66M	$171.33M	$168.13M	$57.95M	n/a
Operating Cash Flow	$74.16M	-$12.45M	-$83.03M	-$117.49M	-$49.03M	$3.75M	-$21.14M	-$3.67M	n/a
Capital Expenditures	$18.16M	$9.86M	$1.57M	$1.50M	$506.0K	$586.0K	$456.0K	$175.0K	n/a
Free Cash Flow	$56.00M	-$22.31M	-$84.59M	-$119.00M	-$49.54M	$3.16M	-$21.59M	-$3.85M	n/a
Shares Outstanding	43.27M	42.55M	38.35M	34.21M	26.70M	20.70M	20.32M	2.65M	n/a
Dividends Per Share	n/a	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	n/a
Weighted Average Diluted Shares	n/a	41.78M	37.60M	29.38M	24.62M	20.55M	6.21M	n/a	n/a
EPS (Basic)	n/a	-$1.59	-$3.07	-$4.62	-$2.52	-$0.67	-$4.32	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView